
SLU-PP-322
CAS: 303760-60-3
SLU-PP-322 is a research peptide in the glp-1 / weight management category. SLU-PP-332 is a small molecule agonist of estrogen-related receptors (ERRs), with highest potency at ERR-alpha (EC50 ~98 nM). MiPeptidos offers SLU-PP-322 in 1 sizes with 99.2% verified purity and full analytical documentation.
How SLU-PP-322 Works
SLU-PP-332 is a small molecule agonist of estrogen-related receptors (ERRs), with highest potency at ERR-alpha (EC50 ~98 nM). ERRs are orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism. By activating ERRs, SLU-PP-332 mimics exercise-induced metabolic adaptations, increasing energy expenditure and endurance without physical activity. It has been termed an "exercise mimetic."
Research Applications
Pricing
| Size | Per Vial | 10-Pack |
|---|---|---|
5mg | $25.95 | $188.95 |
Prices shown per vial from 10-pack. Volume discounts available for 50+ vials — contact us.
HPLC Purity Analysis
Certificate of Analysis
This COA is a representative sample. A batch-specific Certificate of Analysis with full HPLC chromatograms and mass spectrometry data is included with every MiPeptidos order.
Reconstitution Calculator
Inject bacteriostatic water slowly along the vial wall. Gently swirl until dissolved — never shake. Store reconstituted solution at 2-8°C and use within 30 days.
Download Product Brochure
Get our detailed SLU-PP-322 product brochure with specifications, research applications, HPLC analysis data, and reconstitution guide. Available in English and Spanish.
Customer Reviews
Frequently Asked Questions
Specifications
Sequence
N/A (not a peptide; small molecule ERR agonist)
Research Use Only. This product is intended for laboratory research purposes only. Not for human consumption. Handle with appropriate safety precautions.
Related Peptides

Semaglutide
A glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for glycemic control. Widely studied for its role in appetite regulation and metabolic research.

Tirzepatide
A dual GIP/GLP-1 receptor agonist studied for its effects on glucose metabolism and body weight regulation. One of the most researched peptides in the incretin class.

Retatrutide
A triple agonist targeting GIP, GLP-1, and glucagon receptors. Investigated in preclinical and clinical research for its multi-pathway approach to metabolic regulation.

Liraglutide
A GLP-1 receptor agonist with an extended half-life due to fatty acid acylation. Extensively studied for glucose homeostasis and appetite signaling research.